" class="no-js "lang="en-US"> Jean-Philippe Kouakou-Zebouah Archives - Medtech Alert
Friday, March 31, 2023

Breaking News

Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS) ProJenX Announces Formation of Scientific Advisory Board for Development of ALS Treatment NADclinic Group, BioStarks and Do Not Age Announce Exclusive Partnership to Revolutionise Personalised Longevity PathAI Announces Collaboration with GSK on NASH Phase 2b Clinical Trial Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa

Sort by:

Date

Top Post

NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business | MTA

NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business

NEC Corporation and NOI announced that NOI will be realigned as a subsidiary of NEC […]

Read more

Drug Development

 Vida Ventures Closes $825 Million Vida III Fund to Advance Transformative Biomedical Innovations | Pharmtech Focus

Vida Ventures Closes $825 Million Vida III Fund to Advance Transformative Biomedical Innovations

Vida Ventures (“Vida”), a next-generation life sciences venture firm, announced today the closing of Vida Ventures […]

  1. Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis

    Clinical Trials

     Read more
  2. NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business

    Drug Development

     Read more
  3. Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions

    Appointments

     Read more
  4. Sensorion Appoints Khalil Barrage as Interim Chairman of the Board

    Appointments

     Read more
  5. Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China

    Diseases

     Read more